Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 ha-ras oncogene

Molecular Pharmacology

Volumn 49, Issue 6, 1996, Pages 972-979

  Danesi, Romano ^a,b   Nardini, Denise ^b   Basolo, Fulvio ^b   Del Tacca, Mario ^b   Samid, Dvorit ^c   Myers, Charles E ^c  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PHENYLACETIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOPRENYLATION; MITOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL DIVISION; GENES, RAS; HUMANS; MALE; PHENYLACETATES; PROSTATIC NEOPLASMS; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSFECTION;

EID: 0029892886     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Steele, G. D., T. R. T. Osteen, D. P. Winchester, G. P. Murphy, and H. R. Menck. Clinical highlights from the National Cancer Data Base: 1994. CA Cancer J. Clin. 44:71-80 (1994).
2. Parda, D. S., P. J. Thraves, M. R. Kuettel, M.-S. Lee, P. Arnstein, M. E. Kaighn, J. S. Rhim, and A. Dritschilo. Neoplastic transformation of a human prostate epithelial cell line by the v-Ki-ras oncogens. Prostate 23:91-98 (1993).
3. H expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endocrinol. 5:209-216 (1991).
4. Viola, M., F. Fromowitz, S. Oravez, S. Deb, G. Finkel, J. Lundy, P. Hand, A. Thor, and J. Schlom. Expression of ras oneogene p21 in prostate cancer. N. Engl. J. Med. 314:133-137 (1986).
5. Giannakouros, T., and A. I. Magee. Protein prenylation and associated modifications, in Lipid Modifications of Proteins (M. J. Schlesinger, ed.). CRC Press, Boca Raton, FL, 136-162 (1993).
6. Grünler, J., J. Ericsson, and G. Dallner. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim. Biophys. Acta 1212:259-277 (1994).
7. Samid, D., S. Shack, and C. E. Myers. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91:2288-2295 (1993).
8. Castillo, M., M. Martinez Cayuela, M. S. Zafra, and E. Garcia Peregrin. Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis. Mol. Cell. Biochem. 105:21-25 (1991).
9. Samid, D., Z. Ram, W. R. Hudgins, S. Shack, L. Liu, S. Walbridge, E. H. Oldfield, and C. E. Myers. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. 54:891-895 (1994).
10. Thibault, A., D. Samid, M. R. Cooper, W. D. Figg, A. C. Tompkins, N. Patronas, D. J. D. J. Headlee, D. R. Kohler, D. J. Venzon, and C. E. Myers. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75:2932-2938 (1995).
11. Fenton, R. G., H. F. Kung, D. L. Longo, and M. R. Smith. Regulation of intracellular actin polymerization by prenylated cellular proteins. J. Cell. Biol. 117:347-356 (1992).
12. Horoszewiez, J. S., S. S. Leong, E. Kawinski, J. P. Karr, H. Rosenthal, T. M. Chu, E. A. Mirand, and G. P. Murphy. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1809-1818 (1983).
13. Spandidos, D. A., and N. M. Wilkie. Malignant transformation of early passage rodent cells by a single mutated human oneogene. Nature (Lond.) 310:469-475 (1984).
14. Reiss, Y., M. C. Seabra, S. A. Armstrong, C. A. Slaughter, J. L. Goldstein, and M. S. Brown. Nonidentical subunits of p21H-ras farnesyltransferase: peptide binding and farnesyl pyrophosphate carrier functions. J. Biol. Chem. 266:10672-10677 (1991).
15. Sun, J., Y. Qian, A. D. Hamilton, and S. M. Sebti. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res. 55: 4243-4247 (1995).
16. Danesi, R., C A. McLellan, and C. E. Myers. Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation. Biochem. Biophys. Res. Commun. 206:637-643 (1995).
17. Sagami, H., S. Matsuoka, and K. Ogura. Formation of Z,E,E-geranylgeranyl diphosphate by rat liver microsomes. J. Biol. Chem. 266:3458-3463 (1991).
18. Cinatl, J., J. Cinatl, P. Herneiz, H. Rabenau, M. Hovak, R. Benda, H. O. Gumbel, B. Kornhuber, and H. W. Doerr. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Lett. 78:41-48 (1994).
19. Samid, D., A. Yeh, and P, Prasanna. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80:1576-1581 (1992).
20. Lia, L., S. Shack, W. G. Stetler-Stevenson, W. R. Hudgins, and D. Samid. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Invest. Dermatol. 103: 335-340 (1994).
21. Jakovisiak, M., S. Bruno, J. S. Skierski, and Z. Darzynkiewicz. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA 88:3628-3632 (1991).
22. Thompson, T. C., T. L. Timme, D. Kadmon, S. H. Park, S. Egawa, and K. Yoshida. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol. Carcinog. 7:165-179 (1993).
23. Ichikawa, T., J. A. Schalken, Y. Ichikawa, G. D. Steinberg, and J. T. Isaacs. H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. Prostate 18:163-172 (1991).
24. Anwar, K., K. Nakakuki, T. Shiraishi, H. Naiki, R. Yatani, and M. Inuzuka. Presence of ras oncogene mutations and Tinman papillomavirus DNA in human prostate carcinomas. Cancer Res. 52:5991-5996 (1992).
25. P. Tamanoi. Inhibitors of Ras farnesyltransferases. Trends Biochem. Sci. 18:349-353 (1993).
26. Perez-Sala, D., and F Mollinedo. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun. 199:1209-1215 (1994).
27. Ridley, A. J., and A. Hall. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389-399 (1992).
28. Sinensky, M., K. Fantle, and M. Dalton. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res. 54: 3229-3232 (1994).
29. Ueker, D. S., P. S. Obermiller, W. Eckhart, J. R. Apgar, N. A. Berger, and J. Meyers. Genome digestion is a dispensable consequence of physiological ceil death mediated by cytotoxic lymphocytes-T. Mol. Cell. Biol. 12:3060-3069 (1992).
30. Kohl, N. E., S. D Mosser, S. J. deSolms, E. A. Giuliani, D. L. Pompliano, S. L. Graham, R. L. Smith, E. M Scolnick, A. Oliff, and J. B. Gibbs. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Washington D. C.) 260:1934-1937 (1993).
31. James, G. L., J. L. Goldstein, M. S. Brown, T. E. Rawson, T C. Somers, R. S. McDowell, C. W. Crowley, B. K. Lucas, A. D. Levinson, and J. C. Marsters, Jr. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington D. C.) 260:1937-1942 (1993).
32. Gibbs, J. B. Ras C-terminal processing enzymes: new drug targets? Cell 65:1-4 (1991).
33. Thompson, E. B. Apoptosis and steroid hormones. Mol. Endocrinol. 8:665-673 (1994).
34. Hudgins, W R., T. Pineau, T. Sher, F. J. Gonzales, C. E. Myers, and D. Samid. Anticancer activity of phenylacetate and related aromatic fatty acids: correlation with lipophilicity and capacity to activate a nuclear receptor. Proc. Am. Assoc. Cancer Res. 35:391 (1994).